---
title: "Renatus Tactical Acquisition Corp I | 10-K: FY2025 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283962938.md"
datetime: "2026-04-24T08:45:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283962938.md)
  - [en](https://longbridge.com/en/news/283962938.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283962938.md)
---

# Renatus Tactical Acquisition Corp I | 10-K: FY2025 Revenue: USD 0

Revenue: As of FY2025, the actual value is USD 0.

EBIT: As of FY2025, the actual value is USD -7.107 M.

#### Segment Revenue

Renatus Tactical Acquisition Corp I did not generate any operating revenues from its inception on July 2, 2024, through December 31, 2025.

#### Operational Metrics

-   For the year ended December 31, 2025, Renatus Tactical Acquisition Corp I reported a net income of $5,055,742.
-   This net income was primarily driven by investment income of $6,079,742 earned on cash held in the Trust Account.
-   Formation and operating expenses totaled $1,025,873 for the same period.

#### Cash Flow

-   Cash used in operating activities for the year ended December 31, 2025, was -$991,948.
-   Investing activities for the same period resulted in -$242,108,290 in cash used, including $242,103,750 deposited into the Trust Account and -$4,540 in net advances to the Sponsor.
-   Cash provided by financing activities amounted to $243,104,269, comprising proceeds from the IPO and private placement, net of offering costs, and $250,000 from a convertible note.

#### Unique Metrics

-   As of December 31, 2025, Renatus Tactical Acquisition Corp I had cash of $4,031 in its operating bank account and working capital of $388,033.
-   Following its IPO on May 16, 2025, $242,103,750 was placed into a trust account.
-   Total transaction costs for these offerings were $12,213,743, consisting of a $1,207,500 cash underwriting fee, an $8,452,500 deferred underwriting fee, and $2,553,743 in other offering costs.

#### Outlook / Guidance

Renatus Tactical Acquisition Corp I anticipates its current cash of $4,031 outside the Trust Account is insufficient for the next twelve months, raising substantial doubt about its going concern status. The company plans to use these funds for identifying and evaluating target businesses and structuring a business combination. It may seek additional financing, including up to $1,500,000 in convertible loans and a $639,375 Working Capital Convertible Note from the Sponsor, to cover operational needs and transaction costs.

### Related Stocks

- [RTAC.US](https://longbridge.com/en/quote/RTAC.US.md)

## Related News & Research

- [Here's Why We're Not At All Concerned With Renascience's (TSE:4889) Cash Burn Situation](https://longbridge.com/en/news/286861893.md)
- [ZenaTech Advances Three ZenaDrone Defense Platforms Through Blue UAS Certification Pathway | ZENA Stock News](https://longbridge.com/en/news/286910480.md)
- [Is Wall Street Bullish or Bearish on Fastenal Stock?](https://longbridge.com/en/news/286373793.md)
- [Tomas Kiselak resigns from Zenas BioPharma board after term expiration](https://longbridge.com/en/news/286241504.md)
- [Zenas BioPharma Insider Bought Shares Worth $1,012,800, According to a Recent SEC Filing](https://longbridge.com/en/news/286872009.md)